Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors
Article 2020 en
Authors
SG
Smith Giri
AG
Alyssa Grimshaw
SB
Susan Bal
Abstract
1 min read
This study suggests that incorporating daratumumab to backbone regimens may be associated with improved PFS among patients with newly diagnosed HRMM or relapsed or refractory HRMM.
Smith Giri, Alyssa Grimshaw, Susan Bal, Kelly Godby, Prakash Kharel, Benjamin Djulbegović, Saad Z. Usmani, Thierry Façon, Philippe Moreau, Meletios A Dimopoulos, María‐Victoria Mateos, Luciano J. Costa
Kristine A. Frerichs, Christie P.M. Verkleij, Meletios A Dimopoulos, Jhon A. Marin Soto, Sonja Zweegman, Mary H. Young, Kathryn J. Newhall, Tuna Mutis, Niels W.C.J. van de Donk
Meletios A Dimopoulos, Albert Oriol, Hareth Nahi, Jesús F. San Miguel, Nizar J. Bahlis, Saad Z. Usmani, Neil Rabin, Robert Z. Orlowski, Mieczysław Komarnicki, Kenshi Suzuki, Torben Plesner, Sung‐Soo Yoon, Dina Ben Yehuda, Paul G. Richardson, Hartmut Goldschmidt, Donna Reece, Steen Lisby, Nushmia Z. Khokhar, Lisa O’Rourke, Christopher Chiu, Xiang Qin, Mary Guckert, Tahamtan Ahmadi, Philippe Moreau
Discussion(0)
No comments yet. Be the first to comment.